<DOC>
	<DOCNO>NCT02632786</DOCNO>
	<brief_summary>This global , multicenter , Phase 2b , randomize , double-blind , placebo-controlled , two-arm , parallel-group efficacy safety study NEOD001 single agent administer intravenously adults AL amyloidosis hematologic response previous treatment amyloidosis ( e.g. , chemotherapy , autologous stem cell transplant [ ASCT ] ) persistent cardiac dysfunction .</brief_summary>
	<brief_title>The PRONTO Study , Global Phase 2b Study NEOD001 Previously Treated Subjects With Light Chain ( AL ) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Confirmed diagnosis systemic AL amyloidosis 3 . ≥1 prior systemic plasma cell dyscrasia therapy least partial hematologic response 4 . Cardiac involvement 5 . NTproBNP ≥650 1 . NonAL amyloidosis 2 . Meets International Myeloma Working Group ( IMWG ) definition Multiple Myeloma 3 . NTproBNP &gt; 5000 4 . Received Plasma cell direct chemotherapy within 6 month 5 . Received autologous stem cell transplant ( ASCT ) within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>ntprobnp</keyword>
	<keyword>NEOD001</keyword>
	<keyword>Prothena</keyword>
	<keyword>PRONTO</keyword>
	<keyword>amyloid</keyword>
	<keyword>plasma cell dyscrasia</keyword>
	<keyword>immunotherapy</keyword>
</DOC>